1. Home
  2. MOH vs CYTK Comparison

MOH vs CYTK Comparison

Compare MOH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Molina Healthcare Inc

MOH

Molina Healthcare Inc

SELL

Current Price

$206.28

Market Cap

10.5B

Sector

Health Care

ML Signal

SELL

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

SELL

Current Price

$62.30

Market Cap

10.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MOH
CYTK
Founded
1980
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5B
10.7B
IPO Year
2002
2004

Fundamental Metrics

Financial Performance
Metric
MOH
CYTK
Price
$206.28
$62.30
Analyst Decision
Hold
Strong Buy
Analyst Count
19
23
Target Price
★ $209.12
$109.40
AVG Volume (30 Days)
603.2K
★ 2.0M
Earning Date
10-21-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.46
N/A
Revenue
★ $45,426,000,000.00
$13,368,000.00
Revenue This Year
$2.05
$72.63
Revenue Next Year
$8.06
$181.06
P/E Ratio
$145.83
★ N/A
Revenue Growth
★ 11.75
N/A
52 Week Low
$121.06
$54.30
52 Week High
$244.89
$88.31

Technical Indicators

Market Signals
Indicator
MOH
CYTK
Relative Strength Index (RSI) 58.17 36.80
Support Level $188.03 $59.21
Resistance Level $214.60 $67.65
Average True Range (ATR) 7.62 2.01
MACD 2.39 0.31
Stochastic Oscillator 73.74 34.67

Price Performance

Historical Comparison
MOH
CYTK

About MOH Molina Healthcare Inc

Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: